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Abstract
An important question in photobiology asks how Ultraviolet B (UVB, 290 – 320 nm) radiation, 
which mostly absorbs in the outer epidermis of skin, can generate a systemic response such as
immunosuppression. Previous in vitro and ex vivo studies demonstrate UVB-dependent release of 
bioactive molecule-containing microvesicle particles (MVPs) from keratinocytes. Furthermore, 
MVP release is diminished upon antioxidant administration. The purpose of this study is to 
examine UVB-induced MVP release and antioxidant response in vivo. In this IRB-approved study, 
8 male participants with Fitzpatrick type I or II skin were treated with 1000 J/m2 UVB irradiation 
to a 5 by 5 mm area of volar forearm skin. 4 hours later, punch biopsies and erythema
measurements were performed. This procedure was repeated 8 days later following a course of 
oral antioxidants. On average, tissue MVP release increased 1.8-fold (+/- 0.31, P = 0.02) following 
UVB treatment. Following a course of oral antioxidants, the average UVB-induced tissue MVP 
release did not differ from the control (0.9-fold +/- 0.13, P = 0.23). There was no significant change
in UVB-induced erythema between pre- and post-antioxidant administration. These studies
suggest that UVB-MVP are dependent upon reactive oxygen species.
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This study is designed to investigate whether ultraviolet B radiation (UVB) found in sunlight
causes release of microvesicle particles (MVPs) in human skin in vivo, and if antioxidants can 
inhibit their release. Microvesicle particles are small, 100-micron cellular fragments that bud off 
keratinocytes and released into the extracellular environment. MVPs, containing bioactive
contents such as cytokines and Platelet-activating factor (PAF) agonists, are thought to serve a
messenger function within the body and be a mediator of systemic response to UVB radiation of 
the epidermis [1].
Previous studies have demonstrated that the lipid mediator PAF is produced in human skin upon 
exposure to UVB light and leads to systemic immunosuppression [2,3,4]. Furthermore, UVB-
induced PAF production in human skin is blocked by antioxidants [2,3]. Additional studies show
that MVPs are released in human skin upon exposure to both UVB radiation and PAF. While
UVB-mediated MVP release is blocked by pretreatment of cell lines with antioxidants vitamin C 
or N-acetyl cysteine, MVPs are still released upon exposure to the PAF-agonist Carbomyl-PAF 
(CPAF) [5]. These results suggest that UVB-dependent MVP release is mediated via PAF-agonist
production and PAF Receptor (PAFR) activation [5]. 
Previous studies were performed on either human tissue explants or cell cultures, but not on live
humans. Therefore, the purpose of this study is to investigate if UVB radiation induces MVP
formation on human subjects in vivo, and if MVP release can be blocked by antioxidants. Blocking 
MVP release may have clinical utility by reducing systemic inflammatory response upon sun 
exposure and reducing severity of sunburns. 




      




         
        
      
    
        
      
       
         
     
      
          
       
       
   
McGlone 3
Hypothesis/Specific Aims/Research Questions
Upon exposure to UVB radiation, human skin will produce a marked increase in microvesicle
particle formation and release. Additionally, microvesicle particle release due to UVB exposure
will be diminished following oral antioxidant administration. 
Methods
Context/Protocol
This study is designed to test if localized UVB treatment will increase the microvesicle particle
count in the treatment area, and if administering antioxidants will decrease this response. The
amount of vitamin C and vitamin E administered was chosen from a previous study [6] in which 
participants who were given 2000 mg of vitamin C and 1000 mg of vitamin E daily for 8 days had 
a diminished erythematous response to UVB light. These amounts have also been shown to be safe
[6]. Only male participants were recruited to control for fluctuating hormones associated with the
menstrual cycle and any affect they may have on MVP release or inflammatory response. While
the original goal was to enroll twelve participants, contact restrictions secondary to the COVID-
19 pandemic allowed for completion of a statistically-meaningful eight participants. All 
participants fully completed the study. Appointments and procedures for this study were carried 
out in the Pharmacology Translational Unit (PTU), located in the Wright State Physicians building. 
Inclusion Criteria: Adult male subjects aged 21-45 with Fitzpatrick type I or II skin (“fair”
complexion) will be enrolled. A person with Fitzpatrick type I skin always sunburns and never 
tans, while one with Fitzpatrick type II skin sunburns easily with minimal tanning. 






   
   
 
  






        
      
         
  
        




1. Unable to understand informed consent
2. Any condition that compromises wound healing
3. Large volar arm tattoos
4. Currently taking medication(s) known to be a photosensitizer, anti-inflammatories, or 
vitamin C or E
5. Renal compromise or nephrolithiasis
6. History of hypertrophic scarring or keloids
7. Allergy to vitamin C, vitamin E, or lidocaine
8. Use of tanning beds or UVB exposure to volar forearm within the past 3 months
9. Recent (1 week) use of sunscreen to volar forearms
Study Protocol:
Day 0: 
1. Volar forearm skin was photographed and a 5 x 5 mm area of skin treated with 1000 J/m2 
of UVB irradiation, approximately 3 minimal erythema doses (MED; ~350 J/m2). A MED
is the amount of UVB radiation able to induce mild erythema by 24 hours and equivalent
to a minor sunburn. 
2. On the back of the same side, four separate 5 x 5 mm areas of skin were treated with 200 
J/m2, 400 J/m2, 600 J/m2, and 800 J/m2 of UVB irradiation. These areas allowed us to 
measure the effect of antioxidants on dose-dependent UVB-induced erythema. 
   
 
       
       
    
          
     
      
     
    
 
        
 
     
     
    
         
        
      
     
 
 
   
McGlone 5
3. Four hours later, the UVB-treated volar forearm was photographed and erythema was 
measured with a mexameter (non-invasive instrument that measures redness). A 5 mm
punch biopsy was performed on the UVB-irradiated area and another nearby, untreated 
spot on the same volar forearm. The 5 mm punch biopsies were performed as follows: the
area was appropriately sterilized and then anesthetized with 1% lidocaine with 1:100000 
epinephrine. One or two sutures were placed following the punch biopsy and participants
were scheduled to return 10-14 days later for suture removal. Wound care instruction, 
antibiotic ointment, and adhesive bandages were provided. 
Day 1:
1. The UVB-treated areas on the back were photographed and their erythema measured via
mexameter.
2. The participants were dispensed over-the-counter vitamin C (1000 mg capsules) and 
vitamin E (1000 mg capsules). Participants were instructed to take two vitamin C and one
vitamin E capsule daily for 8 days, starting this day. 14 vitamin C capsules and 7 vitamin 
E capsules were given in a 7-day weekly medicine planner, with the appropriate tablets in 
each compartment. The participants completed the first dose (Day 1) in the office and were
instructed to use the medicine planner the following day. Subjects were instructed to bring 
the medicine planner back on day 8 so any remaining capsules could be counted and 
compliance ensured. 
Day 8:
1. Any remaining vitamin capsules in the participant’s medicine planner were counted
   
 
     
   
       
  
 
        
 







   
         
        
           
   
       
       
McGlone 6
2. The contralateral volar forearm was photographed and subsequently treated with UVB 
irradiation. Two skin biopsies were removed 4 hours later (same as day 0).
3. On the contralateral back, 4 small areas of skin were treated with increasing amounts of 
UVB irradiation (same as day 0). 
Day 9:
1. The UVB-treated areas on the contralateral back were photographed and their erythema
measured via mexameter. 
Compensation: Participants were compensated a total of $300 for study completion. 
Compensation was dispensed as follows:
Day 0: $25 for UVB procedures and $50 for skin biopsies
Day 1: $50 for the mexameter readings
Day 8: $25 for UVB procedures and $50 for skin biopsies
Day 9: $100 for mexameter readings and completion of the study
Data Collection
Two primary types of data were collected:
1. Tissue microvesicle particle count: Following the punch biopsy as described above, the
tissue sample was placed in a sterile salt solution containing collagenase and dispase, where
it was stored overnight before microvesicle particle counting. The tissue sample lysate was
collected and centrifuged at 2,000 x g for 20 minutes at 4°C to remove debris. The sample
supernatant was further centrifuged at 20,000 x g for 10 minutes at 4°C for further tissue
and cellular component removal. Microvesicle particles were pelleted from this supernatant
   
 
      
         
 
        
      
       
       
         
     
           
        
    
       
 
 
        
       
   
      
         
         
       
         
McGlone 7
by centrifugation at 20,000 x g for 70 minutes at 4°C. Microvesicle particle concentration 
was determined using a NanoSight NS300, a device that uses dynamic light scattering 
(DLS) and Brownian motion to characterize nanoparticles. 
2. Skin erythema measurement: As described in the protocol above, a mexameter was used 
to measure erythema of UVB-treated area. Adequate time was given to allow an 
erythematic response to develop. A nearby area of skin that was not treated with UVB 
irradiation was read and used as a baseline. Mexameter readings were repeated 5 times at
each site and averaged. The mexameter uses light reflectance to provide a numerical value
of erythema. Specifically, the mexameter emits a known quantity of light and a receiver 
detects the amount of light reflected by the skin. The amount of light the skin absorbs is
calculated from these two numbers. The mexameter displays erythema as a unitless number 
between 0 (lowest) and 999 (highest). As hemoglobin is primarily responsible for this
redness, the mexameter uses two wavelengths of light (green 568 nm light and red 660 nm
light) to measure erythema and minimize noise. 
Data Analysis
All data analysis was completed using Microsoft Excel for Macintosh. Statistical significance of 
MVP release (figure 1) and erythema (figure 2) between control non UVB-treated skin, UVB-
treated skin pre-antioxidant administration, and UVB-treated skin post-antioxidant administration 
was evaluated using a one-tailed paired Student’s t-test on fold change data. A paired t-test was 
used as we are comparing the means of the same group of 8 male participants under varying 
condition, i.e., pre- and post- antioxidant administration. A one-tailed test was selected as we are
only testing a change in tissue MVP release and erythema in one direction. Fold change data, and 
not raw numerical data, was used because of varying basal starting points of tissue MVP
   
 
        
           
        
        
      
       
    
        
 
 
     
      
      
     
       
        
     
       
       
     




concentration and erythema. The magnitude of change with respect to the starting point is of more
interest than the numerical value of the change itself. These t-tests confirmed the first part of our 
hypothesis –there is a significant increase in skin MVP release following UVB irradiation. A two-
tale z-test evaluated the statistical significance of the average fold change in UVB-induced MVP
release and UVB-induced erythema in pre-antioxidant versus post-antioxidant trials. A z-test was 
chosen because the standard deviations of these two populations were known. Comparing these
two populations (pre-antioxidants and post-antioxidants) evaluated the second part of our 
hypothesis, that MVP release is diminished following antioxidant supplementation. Alpha was set
at 0.05 for each statistical test. 
Results
An approximately 2-fold increase in erythema of the volar forearm skin was elicited following 
1000 J/m2 UVB treatment in both the pre-antioxidant and post-antioxidant cohorts (Figures 1A, 
B). These erythematic responses are statistically significant when compared to control non UVB-
treated skin (P = 0.002 pre-antioxidants, P < 0.001 post-antioxidants, Figure 1A). There is no 
appreciable difference in UVB-stimulated erythema between the pre- and post-antioxidant trials
(P = 0.49, Figures 1A, B). Prior to antioxidant administration, the average tissue MVP release
increased 1.8-fold (P = 0.02) upon exposure to 1000 J/m2 UVB irradiation (Figures 2A, B). After 
an 8-day course of antioxidants, the average fold of tissue UVB-induced MVP release was 0.9 and 
not statistically different than the control non UVB-treated sample (P = 0.21, Figures 2A, B). 
Tissue samples collected after antioxidant therapy demonstrated an appreciable reduction (P
0.0074) in UVB-induced MVP release when compared to similar pre-antioxidant samples (Figures
2A, B). 
McGlone 9 












1 28 165 (1.0) 431 (2.6) 159 (1.0) 
2 26 223 (1.0) 406 (1.8) 216 (1.0) 
3 25 113 (1.0) 430 (3.8) 179 (1.0) 
4 29 187 (1.0) 385 (2.1) 230 (1.0) 
5 24 252 (1.0) 443 (1.8) 246 (1.0) 
6 27 123 (1.0) 305 (2.5) 108 (1.0) 
7 23 247 (1.0) 302 (1.2) 240 (1.0) 
8 29 189 (1.0) 354 (1.9) 223 (1.0) 
Mean fold change 
(+/- SEM) 1.0 
2.2 (+/- 0.60) 
P = 0.002 1.0 
z-Test: 
P = 0.49 







     
     
         
      
       
  
    
   
     
       
     
    
      


































Figure 1: UVB-irradiation of human skin 
produces a significant quantifiable erythema
response. A 5 mm x 5 mm area of volar forearm
skin was treated with 1000 J/m2 UVB irradiation
in 8 male subjects. Erythema response of non
UVB-treated control skin and UVB-treated skin
was evaluated and recorded 4 hours later. This
procedure was then repeated following an 8-day
course of vitamin C and E antioxidants.
Mexameter data points were averaged from 3
readings. A) Erythema measurements are
numerically presented as unitless mexameter data
and fold change +/- SEM after being normalized 























Control (No UVB UVB-Treated Pre- UVB-Treated Post-
Treatment) Antioxidants Antioxidants 
McGlone 10 
Subject # Age Control MVP x 1011 / g (Fold) 
UVB MVP x 
1011 / g (Fold) 
Control MVP 




x 1011 / g (Fold) 
1 28 5.1 (1.0) 8.1 (1.6) 5.6 (1.0) 
2 26 10.8 (1.0) 1.6 (0.15) 2.9 (1.0) 
3 25 0.95 (1.0) 1.6 (1.7) 3.6 (1.0) 
4 29 2.8 (1.0) 9.4 (3.3) 6.7 (1.0) 
5 24 6.2 (1.0) 12.0 (1.9) 6.4 (1.0) 
6 27 3.3 (1.0) 5.8 (1.8) 5.6 (1.0) 
7 23 9.5 (1.0) 23.3 (2.5) 4.8 (1.0) 
8 29 0.96 (1.0) 1.5 (1.5) 7.4 (1.0) 
Mean fold change 
(+/- SEM) 1.0 
1.8 (+/- 0.31) 
P = 0.02 1.0 
z-Test: 
P = 0.0074 






     
   
     
        
     
  
       
     
         
      
    
       
      


























































Control (No UVB UVB-Treated Pre- UVB-Treated Post-
Treatment) Antioxidants Antioxidants 
Figure 2: UVB-induced MVP release is
diminished after antioxidant supplementation.
Eight male subjects were treated with 1000 J/m2 
of UVB irradiation to the volar forearm and 5 mm
punch biopsies were collected 4 hours later on
both UVB-treated and control (non UVB-treated)
skin. This procedure was repeated 8 days later on
the contralateral volar forearm following an 8-day 
course of daily 2000 mg vitamin C and 1000 mg
vitamin E antioxidants. A) MVP data are
numerically presented as both particle levels per
gram of sample tissue and fold change +/- SEM
treated skin. B) Skin MVP release data in fold
change +/- SEM are visualized with a bar graph.
   
 
 
        
         
      
    
        
        
      
     
  
       
      
     
        
    
    
      
     
 
     
      
      
          
McGlone 11
Discussion/Conclusion
Upon exposure to UVB-irradiation, there was a significant increase in skin MVP release in vivo. 
These findings are in agreement with previous in vitro and ex vivo studies where cellular cultures
or human skin explants were used [1]. Administration of oral antioxidants vitamin C and E reduced
tissue UVB-induced MVP response to basal (non UVB-treated control) levels, supporting prior in 
vitro and ex vivo findings. Seeing how keratinocyte MVP release is stimulated by both CPAF (PAF
agonist) and UVB-irradiation, it is postulated that UVB-induced MVP release from keratinocytes
is indirectly mediated through activation of PAFR [5]. In vitro studies have found UVB-stimulated 
production of PAF and oxidized glycerophosphocholine PAFR agonists via induction of reactive
oxygen species (ROS) [3,7]. PAF-agonist generation through an ROS-generating pathway 
explains the effectiveness of ROS-neutralizing vitamin C and E antioxidants. Previous data from
Eberling-Konig et al. demonstrate an increased minimal erythema dose (MED, dose required to 
elicit sunburn) and decreased cutaneous blood flow in participants taking antioxidant vitamins. 
These data suggest a protective effect of antioxidants, raising the amount of UVB required to 
obtain a sunburn and decreasing sunburn severity. Our data expands these findings, adding 
diminished systemic immunosuppression to these antioxidants’ repertoire. Of interest, we did not
observe a noticeable decrease in UVB-induced erythema after vitamin C and E administration. 
This is likely secondary to the larger, approximately 3 MED of UVB administered and capable of 
overcoming photoprotective effects.
Future research can evaluate if systemic antioxidant administration significantly affects sunburn 
duration or identify the therapeutic photoprotective dose. Additionally, establishing the time frame
photoprotection occurs after antioxidant administration and how long these effects last after 
cessation may be of interest. The prominent limitations of this study include its small, but still
   
 
        
       
    
          
      
       
 
       
       





significant, sample size (N=8) and the use of a single, moderate dose of UVB irradiation to 
stimulate MVP release. Sample size was negatively affected by the COVID-19 pandemic and 
subsequent limitations on university-sponsored clinical research activities. Stimulating MVP
release with a single ~ 3 MED of UVB may not best represent a population’s typical daily UVB 
exposure, which is more likely to be brief intermittent exposures. Future studies evaluating dose-
dependent UVB-induced MVP release and antioxidant inhibition in vivo may further elucidate this
relationship. 
In brief, we were able to demonstrate and quantify UVB-dependent release of immunosuppressive
MVPs from epidermal keratinocytes in vivo. UVB-induced MVP release was diminished 
following systemic antioxidant administration. These data may have future clinical implications
in treatment and prevention of sunburn and associated immunosuppression. 
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